Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On 14 September, the Old Road Campus joined the 2019 Oxford Open Doors event and welcomed the public into our workplace.

The Old Road Campus is tucked out of the way next to the Churchill Hospital, but it’s home to a lot of really exciting medical research. The Department of Oncology, the Ludwig Cancer Research Institute, the Wellcome Centre for Human Genetics, the Structural Genomics Consortium, the Board Game Group, Oxford Universities Hospital Trust, the Biomedical Research Centre, the Nuffield Department for Population Health, and the Jenner Institute all came together to make the Old Road Campus accessible to anyone who wanted to explore.

Oncology was there to highlight how important clinical trials are to our work.  It’s so important to make sure that our ideas are backed by good data. Often new therapies work for only a subset of patients, making it especially important to design our trials to test the research with the right group of patients.

We were delighted to welcome over 180 visitors during the four hours we were open.  Adults and children discovered medical research through interactive exhibits and conversations with our scientists, many visitors also explored our labs guided by the researchers who work there. People came from across Oxfordshire, and we were really pleased to welcome so many of our neighbours from Headington and Cowley.

Our visitors typically spend an hour with us. Strengthened no doubt by tea and cake – which raised over £100 for the Churchill Partners.  https://www.cancerresearchuk.org/content/churchill-partners

Open Doors began life in 2007; a small project of the Oxford Preservation Trust - www.oxfordpreservation.org.uk.  It’s grown from small beginnings to over 30,000 visitors in 2018. A chance for everyone from Oxfordshire to explore the history and work of Oxford. You can read about the growth of Open Doors in this blog by the Oxford Preservation Trust Director -  https://www.oxfordpreservation.org.uk/content/august-oxford-open-doors-your-invitation-explore-city

If you missed Open Doors this year, keep an eye open for next year’s event.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.